Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

  • Clinical Aspects in the Treatment for Operable and Session II. Chemotherapy and Radiotherapy II. 1. TAE-1
  • Published:

Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results

  • 99 Accesses

  • 49 Citations

Abstract

We developed segmental Lp-TAE, which is transcatheter hepatic sub-subsegmental, subsegmental, or segmental chemoembolization using Lipiodol introduced into the tumor-bearing hepatic sub-subsegment, subsegment, or segment as the target area. A total of 98 patients with nonresectable hepatocellular carcinoma (HCC) undergoing segmental Lp-TAE (Seg-Lp-TAE) were studied, and the relationship between the CT pattern observed after Seg-Lp-TAE (Seg-Lp-CT) and the therapeutic results obtained in those patients was evaluated. Seg-Lp-CT was classified into four types (type I, homogeneous; type II, defective; type III, inhomogeneous; and type IV, only slight accumulation, if any) according to the Lipiodol accumulation pattern observed after Seg-Lp-TAE. The cumulative nonrecurrence rates of type I were higher than those of types II–IV. The cumulative survival rates of type Ia, in which Lp accumulation is also seen around the main tumor, were the highest (93.8% at 1 year, 85.9% at 2 years, 85.9% at 3 years, and 57.3% at 4 years). The cumulative survival rates achieved with Seg-Lp-TAE were 89.2% at 1 year, 69.4% at 2 years, 58.9% at 3 years, 44.0% at 4 years, and 30.2% at 5 years, which were higher than those achieved with conventional Lp-TAE. Seg-Lp-TAE is very useful in the treatment of HCC limited to one sub-subsegment, subsegment, or segment, and it is important to choose subsubsegmental, subsegmental, subsegmental, or segmental Lp-TAE on the basis of the size and site of the tumor as well as the type and the number of feeding arteries.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Chuang VP, Wallace S (1981) Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 140: 51

  2. 2.

    Chuang VP (1988) Superselective hepatic tumor embolization with Tracker-18 catheter. J Intervent Radiol 3: 69

  3. 3.

    Couinaud C (1954) Lobes et segments hepatiques. Notes sur l'architecture anatomique et chirurgicale de foie. Presse Med 62: 709

  4. 4.

    Guo QY, Uchida H, Matsuo N, Nishimura Y, Sakaguchi H, Nishimine K, Hirohashi S, Ohue S, Nagano N, Ohishi H, Tsujii T (1993) Study on the evaluation of recurrence of HCC and the effect after transcatheter hepatic arterial embolization-fluctuations AFP values. Nippon Acta Radiol 53: 195

  5. 5.

    Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y (1985) Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54: 2367

  6. 6.

    Kuroda C, Sakurai M, Monden M, Marukawa T, Hosoki T, Tokunaga K, Wakasa K, Okamura J, Kozuka T (1991) Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma. A study in resected cases. Cancer 67: 81

  7. 7.

    Livraghi T, Vettori C (1990) Percutaneous ethanol injection therapy of hepatoma. Cardiovasc Intervent Radiol 13: 146

  8. 8.

    Matsuo N, Uchida H, Soda S, Ohshima M, Nakano H, Ohishi H, Nagano N, Kitamura I, Nishimura Y, Nishimine K, Yoshioka T (1990) Histopathological study of the resected specimens after segmental Lp-TAE using Lipiodol mixed with anticancer agent for heppatocellular carcinoma—a anti-tumor effect and influence on non-tumor area. Acta Hepatol Jpn 31: 545

  9. 9.

    Matsuo N, Nishimine K, Uchida H, Nagano N, Nishimura Y, Guo QY, Sakaguchi H, Yoshioka T, Ohue S, Ohishi H, Fukui H, Tsujii T (1992) Usefulness of segmental Lp-TAE using Lipiodol mixed with anticancer agent for inoperable hepatocellular carcinoma. Jpn J Gastroenterol 89: 1415

  10. 10.

    Nakamura H, Tanaka T, Hori S, Yoshioka H, Kuroda C, Okamura J, Sakurai M (1983) Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology 147: 401

  11. 11.

    Nakamura H, Hashimoto T, Oi H, Sawada S (1988) Iodized oil in the portal vein after arterial embolization. Radiology 167: 415

  12. 12.

    Nishimura Y, Uchida H, Guo QY, Matsuo N, Ohue S, Nishimine K, Sakaguchi H, Ohishi H, Yoshioka T, Fukui H, Tsujii T (1991) Transcatheter arterial embolization (TAE) for 1,075 cases of hepatocellular carcinoma—evaluation of TAE using Lipiodol mixed with anticancer agents focusing on cumulative survival rate and 69 cases achieving 3-year survival. J Jpn Soc Cancer Ther 26: 2279

  13. 13.

    Ohishi H, Uchida H, Yoshimura H, Ohue S, ueda J, Katsuragi M, Matsuo N, Hosogi Y (1985) Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 154: 25

  14. 14.

    Ohishi H, Uchida H, Ohue S, Matsuo N, Yoshioka T, Hosogi Y, Tsujii T, Yoshida H, Fukai Y, Matsumori T (1986) Diagnostic values and therapeutic effects of transcatheter arterial embolization using Lipiodol (Lp-TAE) for hepatocellular carcinoma. Comparison of medical images and resected specimens. Acta Hepatol Jpn 27: 28

  15. 15.

    Ohishi H, Yoshimura H, Uchida H, Sakaguchi H, Yoshioka T, Ohue S, Matsui T, Takaya A, Tsujii T (1989) Transcatheter arterial embolization using iodized oil (Lipiodol) mixed with an anticancer drug for the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 23: 33

  16. 16.

    Sakaguchi H, Yoshimura H, Nishimura Y, Iwata K, Ohishi H, Uchida H (1990) Behavior of anti-cancer drug of transcatheter hepatic segmental arterial chemoembolization using Lipiodol mixed with an anti-cancer drug followed by gelatin sponge assessed by Tc-99m pertechnetate. Jpn J Cancer Chemother 17: 1725

  17. 17.

    Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H, Koyama H, Iwanaga T (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin and gelatin sponge. Cancer 60: 1194

  18. 18.

    Satoh O, Uchida H, Nishimine K, Yoshioka T, Ohishi H, Tsushima J, Ohue S, Matsuo N (1990) The analysis of superselective catheterization technique; transcatheter segmental arterial embolization using Lipiodol for hepatocellular carcinoma. Jpn J Clin Radiol 35: 685

  19. 19.

    Shiina S, Tagawa K, Unuma T, Terano A (1990) Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. AJR 154: 947

  20. 20.

    Uchida H, Ohishi H, Matsuo N, Sakaguchi H, Yoshioka T, Sato O, Yoshimura H (1989) Transcatheter arterial chemoembolization using Lipiodol mixed with anticancer agent (Lp-TAE) in the treatment of hepatocellular carcinoma. In: Hiramatsu K, Zeitler E, Rossi P (eds) Recent advances in interventional radiology and new vascular imaging. Elsevier, Amsterdam, p 55

  21. 21.

    Uchida H, Ohishi H, Matsuo N, Nishimine K Maeda M, Yoshioka T (1990) Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13: 140

  22. 22.

    Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397

  23. 23.

    Yamasaki S, Hasegawa H, Makuuchi M, Takayama T (1990) Significance of systematic subsegmentectomy of the liver for hepatocellular carcinoma from the viewpoint of the long-term result. Acta Hepatol Jpn 31: 558

Download references

Author information

Correspondence to Kiyoshi Nishimine.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nishimine, K., Uchida, H., Matsuo, N. et al. Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother. Pharmacol. 33, S60–S68 (1994). https://doi.org/10.1007/BF00686670

Download citation

Keywords

  • Carcinoma
  • Survival Rate
  • Cancer Research
  • Hepatocellular Carcinoma
  • Anticancer Drug